NCT06208124View on ClinicalTrials.gov

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung CancerMalignant Melanoma (Cutaneous)
Interventions
DRUG

IMM-6-415

Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.

Trial Locations (5)

77030

MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute, Denver

85258

Honor Health Research Institute, Scottsdale

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Immuneering Corporation

INDUSTRY

NCT06208124 - A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Biotech Hunter | Biotech Hunter